论文部分内容阅读
目的分析新辅助化疗对局部晚期乳腺癌的临床疗效。方法采用AC方案和AP方案治疗68例女性乳腺癌患者,21天为1个周期,两组均化疗2个周期后行乳腺癌改良根治术。结果AC和AP两组原发灶总有效率分别为50%(17/34)和73.5%(25/34),差异有显著意义(X2=4.25,P=0.039,<0.05);两组腋窝淋巴结总有效率分别为58.8%(20/34)和88.2%(30/34),差异有显著性(X2=5.37,P=0.025,<0.05)。结论新辅助化疗具有:降低分期;消灭微小转移灶,减少远处播散及耐药发生;提高患者生存质量和生存率的优点,成为乳腺癌全身治疗的一个重要组成部分,AP方案的疗效明显超过AC方案。
Objective To analyze the clinical effect of neoadjuvant chemotherapy on locally advanced breast cancer. Methods 68 cases of female breast cancer were treated with AC regimen and AP regimen. One cycle was performed in 21 days. Two groups were treated with modified radical mastectomy after 2 cycles of chemotherapy. Results The total effective rates of AC and AP were 50% (17/34) and 73.5% (25/34) respectively, with significant difference (X2 = 4.25, P = 0.039, <0.05) The total effective rates of lymph nodes were 58.8% (20/34) and 88.2% (30/34) respectively, with significant difference (X2 = 5.37, P = 0.025, <0.05). Conclusion Neoadjuvant chemotherapy has the following advantages: reducing staging, eliminating micrometastases, reducing distant spread and drug resistance, improving the quality of life and survival rate of patients, becoming an important part of systemic treatment of breast cancer. The efficacy of AP regimen is obvious More than AC program.